

## NEW STUDY HIGHLIGHTS POSITIVE OUTCOMES USING MYRIAD MATRIX™ AND MYRIAD MORCELLS™ IN COMPLEX TRAUMATIC WOUNDS

### Highlights

- Clinical outcomes from the use of AROA's Myriad Matrix and Myriad Morcells products have been described in a new peer reviewed study published in the September issue of industry leading journal, *ePlasty*.
- The retrospective case series assessed 13 complex traumatic wounds across ten patients, in a single facility between January 2021 to February 2023.
- The study found the average time to soft tissue coverage and fill was 23.4±9.2 days, with a median product application of 1.0, and no reported complications from study participants.
- The study findings add to a growing body of evidence supporting the efficacy of the Myriad portfolio in trauma reconstruction procedures.
- With an overall TAM of US\$740m, the Myriad™ portfolio is expected to continue delivering strong growth for the company.<sup>1</sup>

Aroa Biosurgery Limited (ASX: ARX, 'AROA or the 'Company') is pleased to announce the publication of a new retrospective pilot case series of Myriad Matrix™ and Myriad Morcells™ in the surgical management of contaminated volumetric soft tissue defects.

The peer reviewed study, published in the September issue of industry leading journal, *ePlasty*, is entitled, "*Ovine Forestomach Matrix in the Surgical Management of Complex Volumetric Soft Tissue Defects: A Retrospective Pilot Case Series*".<sup>2</sup>

The new study outlines the clinical effectiveness of Myriad Matrix™ and Myriad Morcells™ in complex traumatic wound reconstruction procedures.

The retrospective case series assessed 13 complex traumatic wounds across ten patients, including injuries from motor vehicle accidents, abdominal dehiscence following hernia repair, Fournier's Gangrene, compartment syndrome and pressure injuries, at a single US Level 1 trauma center, between January 2021 and February 2023.

The study found the average time to soft tissue coverage and fill was 23.4±9.2 days, with a median product application of 1.0. No complications were reported from the study cohort.

This retrospective pilot case series builds on an increasing body of evidence demonstrating that AROA ECM products can be used to facilitate the formation of well vascularized soft tissue in patients with trauma injuries.

AROA CEO Brian Ward says: "We're pleased to see publication of this peer reviewed study describing the outcomes of Myriad in trauma procedures. As previously signaled, with a TAM of US\$740m, we

<sup>1</sup> Management's estimate based on 2022 market sales data (ldata Soft Tissue Repair Market 2022.)

<sup>2</sup> Cormican, M T, Creel, N J Bosque, B A, Dowling S G, Rideout P P and Vassy WM (2023). "*Ovine Forestomach Matrix in the Surgical Management of Complex Volumetric Soft Tissue Defects: A Retrospective Pilot Case Series*". *ePlasty*, September 2023.

For personal use only



expect the Myriad portfolio to continue driving strong growth. Based on our estimates, over 86,000 trauma procedures are performed in the US each year, and the TAM for those procedures is approximately US\$300m.”

The full study is available online, [here](#).

< ENDS >

**Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.**

**About Aroa Biosurgery:**

Aroa Biosurgery is a soft-tissue regeneration company committed to ‘unlocking regenerative healing for everybody’. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine forestomach. AROA has commercialised four product families based on its AROA ECM technology, targeting chronic wounds, hernia, soft tissue, and breast reconstruction. Over 6 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. AROA has regulatory approvals in more than 50 countries. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). [www.aroa.com/](http://www.aroa.com/)

**Contact Details**

Sarah Tora  
Corporate Communications Manager  
+64 21 531043  
[sarah.tora@aroabio.com](mailto:sarah.tora@aroabio.com)

For personal use only